Evidence map›Paper›PMID 37240218›Full record

ArticleInternational journal of molecular sciences2023

DNA Repair Pathway in Ovarian Cancer Patients Treated with HIPEC.

Dominika Flasarova, Katerina Urban, Ondrej Strouhal, Dusan Klos, Radmila Lemstrova, Pavel Dvorak, Pavel Soucek, Beatrice Mohelnikova-Duchonova

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Dominika FlasarovaDepartment of Oncology, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic.ORCID 0000-0002-9064-4269
Katerina UrbanDepartment of Oncology, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic.ORCID 0000-0002-8201-171X
Ondrej StrouhalDepartment of Oncology, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic.
Dusan KlosDepartment of Surgery I, Faculty of Medicine and Dentistry, University Hospital Olomouc, 779 00 Olomouc, Czech Republic.ORCID 0000-0002-3097-4418
Radmila LemstrovaDepartment of Oncology, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic.
Pavel DvorakBiomedical Center, Faculty of Medicine in Pilsen, Charles University, 323 00 Pilsen, Czech Republic.ORCID 0000-0002-2124-7219
Pavel SoucekDepartment of Toxicogenomics, National Institute of Public Health, 100 00 Prague, Czech Republic.ORCID 0000-0002-4294-6799
Beatrice Mohelnikova-DuchonovaDepartment of Oncology, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic.
Palacký University Olomouc · CZCharles University · CZNational Institute of Public Health · CZUniversity Hospital Olomouc · CZ

Funding

Czech Health Research Council NU22-08-00186Palacky University IGA_2022_003
6 · The paper itself

Abstract

DNA repair pathways are essential for maintaining genome stability, and understanding the regulation of these mechanisms may help in the design of new strategies for treatments, the prevention of platinum-based chemoresistance, and the prolongation of overall patient survival not only with respect to ovarian cancer. The role of hyperthermic intraperitoneal chemotherapy (HIPEC) together with cytoreductive surgery (CRS) and adjuvant systemic chemotherapy is receiving more interest in ovarian cancer (OC) treatment because of the typical peritoneal spread of the disease. The aim of our study was to compare the expression level of 84 genes involved in the DNA repair pathway in tumors and the paired peritoneal metastasis tissue of patients treated with CRS/platinum-based HIPEC with respect to overall patient survival, presence of peritoneal carcinomatosis, treatment response, and alterations in the

Indexed as

DNA GlycosylasesHyperthermia, InducedOvarian NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyDisease-Free SurvivalDNA RepairFemaleHumansHyperthermic Intraperitoneal ChemotherapyRetrospective StudiesSurvival RateDNA GlycosylasesNEIL1 protein, humanbiomarkersDNA repairHIPECovarian cancer

Identifiers

PMID37240218
PMCPMC10219140
OpenAlexW4376875155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.